A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | MicrobiomeTrials
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-11-30Est. Completion: 2033-02
Enrollment target: 520 participants
Locations
University of Arizona Cancer Center /ID# 285339, Tucson, Arizona, United States
Toi Clinical Research - Whittier /ID# 284462, Cerritos, California, United States
University of California Los Angeles /ID# 282444, Los Angeles, California, United States
University Of Colorado - Anschutz Medical Campus /ID# 283478, Aurora, Colorado, United States
MedStar Georgetown University Hospital /ID# 283734, Washington D.C., District of Columbia, United States
Cleveland Clinic Florida /ID# 283692, Weston, Florida, United States
Northwest Georgia Oncology Centers /ID# 284769, Marietta, Georgia, United States
Rush University Medical Center /ID# 283095, Chicago, Illinois, United States
Beth Israel Deaconess Medical Center /ID# 285204, Boston, Massachusetts, United States
Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 282591, Grand Rapids, Michigan, United States
The Mount Sinai Hospital /ID# 283535, New York, New York, United States
Columbia University Medical Center /ID# 283510, New York, New York, United States
Weill Cornell Medicine - Cornell University /ID# 283712, New York, New York, United States
Other microbiome trials you might be interested in